What are you doing to safeguard patient information?
“We start by having a discussion with patients and letting them know about available resources, but that they have to accept some responsibility themselves,” says one urologist.
“We start by having a discussion with patients and letting them know about available resources, but that they have to accept some responsibility themselves,” says one urologist.
Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
The phase 1 study is set to begin later this year.
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.
The conversation covers practical, case-based strategies for counseling MSM patients.
The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates,
Howard B. Goldman, MD, discusses the rationale and development process for the Glean Urodynamics System.
The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.
“Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with…